

CLS Q2 2023 - In the right direction

Redeye provides an update in relation to CLS' Q2 2023 report. The results fairly aligned with our expectations, with sales of SEK1.3m (SEK0.4m) and an EBIT of SEK-17.0m (SEK-18.7m). We argue the company's outlook is better than it has been in many years and look forward to the rest of 2023. We have only made minor estimate changes based on last week's report. The changes do not render any changes in our fair value range, including a base case of SEK0.4.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

CLS Q2 2023 - In the right direction